soul trial oral semaglutide cardiovascular outcomes nejm 2025 results New in the May 29, 2025, issue of NEJM: Sotatercept in Pulmonary Arterial Hypertension (ZENITH phase 3 trial) https://nej.md/4iYkLbj and (SOUL trial) https://nej.md/4hHII5M Upadacitinib for Giant-Cell Arteritis Semaglutide and Cardiovascular Outcomes in

By The Wondr Health Team Obesity and weight-related chronic conditions are one of the most pressing challenges in the modern workplace

O = Reduction in composite CV events (MACE) and their individual components

We use a fine needle to inject VOLUMA XC into the areas of your cheeks that need volume, resulting in immediate lifting and contouring

The future of GLP-1 therapy lies in this thoughtful integration of precise dosing strategies with comprehensive wellness approaches, always under careful medical guidance

In this study, SW837 rectal cancer cells, and HCT116 colon cancer cells were utilised as an in vitro model of inherently radioresistant, and radiosensitive CRC, respectively

a single skipped week is not the problem, but chronic gaps are